BMS-754807

For research use only. Not for use in humans.

目录号：S1124

CAS No. 1001350-96-4

BMS-754807是一种有效的IGF-1R/InsR可逆性抑制剂，在无细胞试验中IC50为1.8 nM/1.7 nM，对Met，Aurora A/B，TrkA/B和Ron作用稍弱，对Flt3， Lck，MK2，PKA，PKC等几乎没有抑制活性。Phase 2。

规格

价格

库存

购买数量

5mg	RMB 1480.09	现货
10mg	RMB 2214.12	现货
50mg	RMB 6299.66	现货
200mg	RMB 16953.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的BMS-754807发表文献29篇：

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2485

PubMed: 31969334 ( click the link to review the publication )

Sci Signal, 2020, 26;13(633):eaba3176

PubMed: 32457113 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Breast Cancer Res Treat, 2020, 10.1007/s10549-020-05927-5

PubMed: 32940848 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3201

PubMed: 31324758 ( click the link to review the publication )

Cell Rep, 2019, 28(12):3224-3237

PubMed: 31533043 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0268-y

PubMed: 31316177 ( click the link to review the publication )

Cytotherapy, 2019, 21(6):619-630

PubMed: 30956007 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1665952

PubMed: 31559898 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Cancer Res, 2018, 78(14):3995-4006

PubMed: 29669759 ( click the link to review the publication )

Endocrinology, 2018, 159(1):285-296

PubMed: 29029116 ( click the link to review the publication )

Brain Res, 2018, 1678:407-418

PubMed: 29137974 ( click the link to review the publication )

Oncotarget, 2018, 9(56):30869-30882

PubMed: 30112114 ( click the link to review the publication )

Drug Deliv, 2018, 25(1):241-255

PubMed: 29334272 ( click the link to review the publication )

JCI Insight, 2018, 3(8)97398

PubMed: 29669935 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Genes Dev, 2017, 31(6):553-566

PubMed: 28404630 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):88-101

PubMed: 28062706 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(11)

PubMed: 29099049 ( click the link to review the publication )
Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(7):1182-96

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(5):e0126867

PubMed: 25962155 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5866-77

PubMed: 25168481 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(11):2984-94

PubMed: 23549869 ( click the link to review the publication )

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

产品描述

特性

胰岛素样生长因子-1R/IR家族激酶的多重抑制剂

靶点

Insulin Receptor ^[1] (Cell-free assay)	IGF-1R ^[1] (Cell-free assay)	TrkB ^[1] (Cell-free assay)	Met ^[1] (Cell-free assay)	TrkA ^[1] (Cell-free assay)	点击更多
1.7 nM	1.8 nM	4.1 nM	5.6 nM	7.4 nM	点击更多

体外研究

BMS-754807 有效抑制人类多种不同组织来源的肿瘤细胞系的生长，包括间充质（尤文氏肉瘤，横纹肌肉瘤，神经母细胞瘤，和脂肪肉瘤），上皮（乳腺，肺，胰腺，结肠，和胃），和造血（多发性骨髓瘤和白血病）组织，IC50值从5 nM 到 365 nM。BMS-754807 抑制 IGF-1R-Sal 细胞和 RH41细胞增殖，IC50分别为7 nM 和5 nM。BMS-754807作用于IGF-1R-Sal, Rh41 和 Geo细胞，抑制IGF-1R磷酸化，IC50分别为13 nM, 6 nM 和 21 nM。BMS-754807作用于 IGF-1R-Sal, Rh41 和Geo细胞，抑制Akt磷酸化，IC50 分别为22 nM, 13 nM 和 16 nM。BMS-754807诱导Rh41细胞凋亡。^[1] BMS-754807作用于IGF-Sal 细胞系，抑制IGF-1R (IC50 = 13nM) 和下游靶点Akt (IC50 = 22nM) 和MAPK(IC50 = 13nM) 的磷酸化。^[2] 在儿科临床前期试验计划（PPTP）中，BMS-754807作用于23种细胞系，平均EC50值为0.62 µM。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Formulation	Activity Description	PMID
IGF-Sal	M2flSGtqdmG\|ZTDhd5NigQ>?			MWrpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEmJRj2xVkApUUN3MDC9JFE{dk1rIHHu[EB1cGViZH;3cpN1emWjbTD0ZZJo\XS\|IFHreEApUUN3MDC9JFIzdk1rIHHu[EBOSVCNIDjJR\|UxKD1iMUPuUUk>	MnzuNVk4PzhyMkS=
IGF-Sal	MnTnS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?			M4LhVGlEPTB;NzDuUS=>	M{jsR\|E6Pzd6MEK0
CCRF-CEM (ALL)	NYm1cFV4T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4roZ542KM7:TR?=	NH\xUI1FVVOR	NFLyR2xKSzVyPUGuNlM6KM7:TR?=	M4jKUlE6QTl4Mkey
PC3	NEniNotIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2nlUJ42KM7:TR?=	NULaTWFHTE2VTx?=	MoDTTWM2OD1yLkm2OUDPxE1?	NIG2OnUyQTl7NkK3Ni=>
JD	MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NGXsSXl,PSEQvF2=	NFjMRZNFVVOR	M3PYc2lEPTB;MD6zPVEh\|ryP	NHS3Z4wyQTl7NkK3Ni=>
DU145	NILuV3VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NUe1Onp[hjVizszN	NXz1UVVZTE2VTx?=	MVnJR\|UxRTFwNE[1JO69VQ>?	NWTleFdIOTl7OU[yO\|I>
KAG	NWTz[YdDT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NEm4XoR,PSEQvF2=	MkO3SG1UVw>?	MlP0TWM2OD1zLk[2OUDPxE1?	M{i1[VE6QTl4Mkey
K-562 (CML)	MmTuS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFK0NnV,PSEQvF2=	NWLwT5ltTE2VTx?=	NGLUfIZKSzVyPUKuN\|AzKM7:TR?=	NYLRdpZ7OTl7OU[yO\|I>
B6-P210 (Murine ALL)	MmPLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Ml3BglUh\|ryP	NH3hcGFFVVOR	MX\JR\|UxRTFwMkmzJO69VQ>?	NHLT[2MyQTl7NkK3Ni=>
LN CAP-FGC	MX\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M1joRZ42KM7:TR?=	M4LXN2ROW09?	M2TLTmlEPTB;MT60N\|Qh\|ryP	MkDNNVk6QTZ{N{K=
VW	MmT2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NWHFbpIxhjVizszN	M1\ENmROW09?	MlvITWM2OD1yLkCxPUDPxE1?	NXfjdoxkOTl7OU[yO\|I>
MV411 (B Myelomonocytic)	MoDhS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3TWbJ42KM7:TR?=	M37Qc2ROW09?	MnPVTWM2OD1yLkOzJO69VQ>?	M3rTWVE6QTl4Mkey
MDA-PCa-2b	NVviO\|VwT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NXjOdXo{hjVizszN	NVrZ[md1TE2VTx?=	MmPITWM2OD1yLkC5PEDPxE1?	MWqxPVk6PjJ5Mh?=
LG	NWO0OXppT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	Moq2glUh\|ryP	MUXEUXNQ	NVHsPZBuUUN3ME2wMlA{QCEQvF2=	M4frblE6QTl4Mkey
RS411 (B cell precursor-ALL)	MlLKS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NXP2UWlkhjVizszN	NV3lUnVvTE2VTx?=	MY\JR\|UxRTBwMUCyJO69VQ>?	NF\Ub5EyQTl7NkK3Ni=>
22-r-1	MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mk\3glUh\|ryP	Mo\vSG1UVw>?	NVPEepo2UUN3ME2wMlE4PSEQvF2=	NYS5NnJvOTl7OU[yO\|I>
5838	MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVLSW2RDhjVizszN	NEDROFVFVVOR	MUTJR\|UxRTBwMEO0JO69VQ>?	M1exSVE6QTl4Mkey
P388 (Murine)	NFnqbWlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1qyRp42KM7:TR?=	MoC5SG1UVw>?	Ml\WTWM2OD12LkK3JO69VQ>?	M1;aVlE6QTl4Mkey
A2780/S	NIC3ZXJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MYn+OUDPxE1?	MYXEUXNQ	MUfJR\|UxRTBwMUKyJO69VQ>?	M3L1XFE6QTl4Mkey
RDES	MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NUPUeYdHhjVizszN	Mn;VSG1UVw>?	MmXsTWM2OD1yLkCxNkDPxE1?	MoHRNVk6QTZ{N{K=
B6-T315I (Murine B-ALL)	M2jiR2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NUnn[mp4hjVizszN	NWHNT3JRTE2VTx?=	M4DIfGlEPTB;Mj64N{DPxE1?	MnTvNVk6QTZ{N{K=
TOV 112D	NUHFW441T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NUPxTVlVhjVizszN	NYDaNodVTE2VTx?=	MV\JR\|UxRTJwMUS2JO69VQ>?	NImxNngyQTl7NkK3Ni=>
TC32	M3nWSWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NUna[XNQhjVizszN	M1npe2ROW09?	NIDi[YVKSzVyPUCuNFA5KM7:TR?=	M1[0ZlE6QTl4Mkey
HL60 (acute myelocytic)	M2XZVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MlPrglUh\|ryP	M4LROGROW09?	MmTETWM2OD1yLkGyJO69VQ>?	NWPwZZp1OTl7OU[yO\|I>
TOV 21G	Mn\kS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NX\D[WpnhjVizszN	M2nDU2ROW09?	NWDQcXc6UUN3ME20MlI4QSEQvF2=	Ml\4NVk6QTZ{N{K=
TC71	NIT4U3BIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M37zT542KM7:TR?=	M1:xW2ROW09?	MYrJR\|UxRTBwMEG0JO69VQ>?	NV3rXFhpOTl7OU[yO\|I>
HPN-ALL (T-cell)	MlnxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NYfuWHU1hjVizszN	MmHVSG1UVw>?	MXTJR\|UxRTBwNUKg{txO	M4q4SFE6QTl4Mkey
A2780R	NFTqTpRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3PpcZ42KM7:TR?=	Mm\GSG1UVw>?	MUnJR\|UxRTFwNU[0JO69VQ>?	M3joOVE6QTl4Mkey
Rh1	MWnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnfNglUh\|ryP	NXnpdW1rTE2VTx?=	NX\0VnhLUUN3ME2wMlAzPyEQvF2=	MWGxPVk6PjJ5Mh?=
Kasumi-1 (acute myeloid)	NIfWU3hIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NUPRWGZJhjVizszN	Ml7iSG1UVw>?	Mm\OTWM2OD1yLkG2JO69VQ>?	NWWxW3lMOTl7OU[yO\|I>
sk-ov-3	M4LWe2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MoX1glUh\|ryP	M1XtV2ROW09?	NWfMb2MzUUN3ME21MlEh\|ryP	NH20d2gyQTl7NkK3Ni=>
ME	NFj3SGZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NIDvXYt,PSEQvF2=	MnjtSG1UVw>?	MWnJR\|UxRTBwMEG1JO69VQ>?	MnHDNVk6QTZ{N{K=
L1210 (Murine lymphocytic)	MYjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4W3[J42KM7:TR?=	M1PrZWROW09?	M2nFS2lEPTB;Mj6zPUDPxE1?	NIrSd44yQTl7NkK3Ni=>
sw-626	MUPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYSwTVhOhjVizszN	MWnEUXNQ	NHPMZ5BKSzVyPUKuN\|A3KM7:TR?=	NELNOncyQTl7NkK3Ni=>
CTR	MnraS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MX3+OUDPxE1?	MXHEUXNQ	MXXJR\|UxRTBwMkWzJO69VQ>?	NFrLeG4yQTl7NkK3Ni=>
ML2 (Myelomonocytic)	Ml;XS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MnHNglUh\|ryP	M3Hm[WROW09?	M4\3WGlEPTB;MD6wPUDPxE1?	MVKxPVk6PjJ5Mh?=
ovcar-3	NGTJ[ItIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NEDyfoh,PSEQvF2=	MU\EUXNQ	M2ThS2lEPTB;NTFOwG0>	M16wU\|E6QTl4Mkey
Rh36	MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MYH+OUDPxE1?	NYHDWoRHTE2VTx?=	MlzLTWM2OD1zLkSzNkDPxE1?	MUOxPVk6PjJ5Mh?=
MOLM-13 (acute myeloid)	MWLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MmPvglUh\|ryP	MknKSG1UVw>?	NEDBUIRKSzVyPUCuOFIh\|ryP	M37EZVE6QTl4Mkey
ovcar-4	MUfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnnwglUh\|ryP	MYXEUXNQ	NWe4R4xPUUN3ME2xJO69VQ>?	NF;JS24yQTl7NkK3Ni=>
Rh41	NFPsXVFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M4XMXZ42KM7:TR?=	MUfEUXNQ	MoLRTWM2OD1yLkCwOUDPxE1?	MmjxNVk6QTZ{N{K=
Mutz 2 (acute myeloid)	MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M17lPZ42KM7:TR?=	Mle1SG1UVw>?	MVrJR\|UxRTFwMUWg{txO	MYOxPVk6PjJ5Mh?=
ovcar-5	M2HQSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MYD+OUDPxE1?	NX3WfIxTTE2VTx?=	MmXQTWM2OD1yLkC1JO69VQ>?	MmroNVk6QTZ{N{K=
RD1	MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3HYfp42KM7:TR?=	MnXkSG1UVw>?	MYLJR\|UxRTBwME[4JO69VQ>?	M3TKTlE6QTl4Mkey
OCI-AML 2 (acute myeloid)	NEjtW4VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NHvWRVF,PSEQvF2=	MlTVSG1UVw>?	NEmyUmZKSzVyPUOuN\|Mh\|ryP	MYixPVk6PjJ5Mh?=
786-O	MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NGL4PY5,PSEQvF2=	M3Kx[2ROW09?	MUPJR\|UxRTFwNkS3JO69VQ>?	MoHUNVk6QTZ{N{K=
A673	M4TNcmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MmH1glUh\|ryP	NH3zSZdFVVOR	M2XlN2lEPTB;MD60NFgh\|ryP	MWixPVk6PjJ5Mh?=
TALL-1 (T-cell)	MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MmH5glUh\|ryP	NETMeHVFVVOR	NHLtbo5KSzVyPUGuNlgh\|ryP	MmjuNVk6QTZ{N{K=
151-B	NEjycXdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MYD+OUDPxE1?	MnS2SG1UVw>?	NUjRdng6UUN3ME2yMlY4KM7:TR?=	MnvrNVk6QTZ{N{K=
PFSK-1	NX\PPZA1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXX+OUDPxE1?	NWHt[4NCTE2VTx?=	NVfYUJlLUUN3ME2wMlE{OiEQvF2=	MU[xPVk6PjJ5Mh?=
THP-1	MoC0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MmXvglUh\|ryP	NGHxO\|NFVVOR	NG\zU2VKSzVyPU[uOVgh\|ryP	M{Tx[FE6QTl4Mkey
HEK293	M1:xbWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1Xxdp42KM7:TR?=	NHfib3hFVVOR	MUjJR\|UxRTBwOUG1JO69VQ>?	NIHiZ2UyQTl7NkK3Ni=>
DAOY	MkLUS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MmPmglUh\|ryP	NHzUPZRFVVOR	NIfjbGVKSzVyPUGuPVc6KM7:TR?=	NWrXO2xFOTl7OU[yO\|I>
SET2	M{X5VGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NGW2OGp,PSEQvF2=	MUnEUXNQ	MYDJR\|UxRTBwMkm4JO69VQ>?	Mli3NVk6QTZ{N{K=
HTB-46	NXL5fFFsT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1LVWp42KM7:TR?=	NFfTNVNFVVOR	M2roUGlEPTB;NT6yOUDPxE1?	M37OOlE6QTl4Mkey
SK-NAS	MlrLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXP+OUDPxE1?	NXvvZ4dUTE2VTx?=	MUDJR\|UxRTBwNEm3JO69VQ>?	MnHpNVk6QTZ{N{K=
CTLL2	NXX4PXlwT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NVTDOFl2hjVizszN	MYPEUXNQ	MXHJR\|UxRjFwMECg{txO	NHfXUG0yQTl7NkK3Ni=>
HTB-47	M33PbGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MWD+OUDPxE1?	Mm\tSG1UVw>?	NF7ZSZhKSzVyPUKuNFU3KM7:TR?=	M4rBbVE6QTl4Mkey
LAN-1	M2P3SWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVf+OUDPxE1?	NVXsSoRCTE2VTx?=	MUTJR\|UxRTBwMESg{txO	NGXBVVMyQTl7NkK3Ni=>
ST486	MkTxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MnrCglUh\|ryP	M13ISWROW09?	MnjrTWM2OD1zLkG5JO69VQ>?	M3LMbVE6QTl4Mkey
HS766T	NUnzVndsT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NV\CZY1OhjVizszN	MnL0SG1UVw>?	NGLLeJdKSzVyPUKuNFAyKM7:TR?=	M3\vPFE6QTl4Mkey
IMR-32	MnvQS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Ml\PglUh\|ryP	M3zHXWROW09?	MoHPTWM2OD1yLkK2NUDPxE1?	M2O0b\|E6QTl4Mkey
Daudi (Burkitt's)	Mke3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Mn\6glUh\|ryP	Mm\NSG1UVw>?	M3vHbWlEPTB;Mj62N\|ch\|ryP	M2fLO\|E6QTl4Mkey
Aspc-1	Ml3CS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MYT+OUDPxE1?	M2PIfGROW09?	MWjJR\|UxRTBwM{e5JO69VQ>?	NW\aS2dWOTl7OU[yO\|I>
SK-NSH	NG[yfZFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NE\vSGd,PSEQvF2=	M{jkbGROW09?	NV7yR3V2UUN3ME2wMlE{QSEQvF2=	NF;ZWmUyQTl7NkK3Ni=>
MEC-1 (Chronic B cell)	MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NIi1doF,PSEQvF2=	NXrHVGJ3TE2VTx?=	NVvCT5liUUN3ME2yMlY{PyEQvF2=	Ml;HNVk6QTZ{N{K=
Capan-2	NHHsOlJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MXf+OUDPxE1?	M1nXdWROW09?	NYG2eFk4UUN3ME2xMlc4PCEQvF2=	M33JRVE6QTl4Mkey
SHSY5Y	NFHObZBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MWH+OUDPxE1?	NY\EeIRWTE2VTx?=	NVHRfHNoUUN3ME2wMlExPiEQvF2=	MU[xPVk6PjJ5Mh?=
U937 (Histioocytic)	NVjUSG9wT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4TqcJ42KM7:TR?=	NWnRUYROTE2VTx?=	MX;JR\|UxRjVwMECg{txO	NF7xSJIyQTl7NkK3Ni=>
Bxpc-1	NYXBe2dwT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NXvYWVFMhjVizszN	MUjEUXNQ	MnTYTWM2OD1zLkmyOEDPxE1?	NHjmemcyQTl7NkK3Ni=>
Bxpc-3	M1LJd2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NHjHb2N,PSEQvF2=	M4PwWmROW09?	M1izUmlEPTB-NT6wNEDPxE1?	M4jQRVE6QTl4Mkey
HTB-92	NIm1XoFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MoLCglUh\|ryP	NFXhWFZFVVOR	M4r5bWlEPTB;MT6wNkDPxE1?	NGfHfGoyQTl7NkK3Ni=>
OCI-LY10 (B-cell)	NXnKWW1{T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NU\LPFkxhjVizszN	NYXrSnJnTE2VTx?=	M2\H[GlEPTB;MD60OUDPxE1?	MV2xPVk6PjJ5Mh?=
PANC-1	Mmn2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MnW1glUh\|ryP	MX7EUXNQ	MnLWTWM2OD53LkCwJO69VQ>?	NHnTeHEyQTl7NkK3Ni=>
To184.T	Mln2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NXLKdot2hjVizszN	NFfYUXJFVVOR	MVrJR\|UxRTBwNE[5JO69VQ>?	NXnEfXRTOTl7OU[yO\|I>
OCI-LY19 (B-cell)	M37VNmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MX3+OUDPxE1?	NVzSVYh7TE2VTx?=	MoK1TWM2OD1yLkSg{txO	NHvXeGsyQTl7NkK3Ni=>
PANC-1 BM	NEe3cHlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3jpVp42KM7:TR?=	NUHaR\|lkTE2VTx?=	M4TJRmlEPTB-NT6wNEDPxE1?	NX;DOnRIOTl7OU[yO\|I>
SA-4	MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MVv+OUDPxE1?	MlHHSG1UVw>?	NVTTcIM4UUN3ME2xMlMxOSEQvF2=	NYTTSI1[OTl7OU[yO\|I>
RPMI 8226	NYDteWhtT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1fBNJ42KM7:TR?=	MUHEUXNQ	NW\je5ZtUUN3ME2xMlI6OyEQvF2=	MoPQNVk6QTZ{N{K=
HPAF-II	MnXuS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M4\zeZ42KM7:TR?=	Mo\DSG1UVw>?	NXfEZWdKUUN3ME2wMlY1PCEQvF2=	MnLINVk6QTZ{N{K=
SHP-77	MkLrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXX+OUDPxE1?	NUDMZ\|VmTE2VTx?=	NHK4XI5KSzVyPUGuPFg5KM7:TR?=	NUKxXmNsOTl7OU[yO\|I>
U266 B1	Mn\xS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1fMU542KM7:TR?=	NGnUOVJFVVOR	NFXHfWlKSzVyPUGuOlY6KM7:TR?=	MYexPVk6PjJ5Mh?=
Hs700t	MkK1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NUfoN2FnhjVizszN	MnLRSG1UVw>?	NX[wRY1{UUN3ME2wMlI{OSEQvF2=	NHHIXowyQTl7NkK3Ni=>
NCI-446	MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NF;FVGl,PSEQvF2=	MYnEUXNQ	MWnJR\|UxRTFwMUW0JO69VQ>?	NGPlWGwyQTl7NkK3Ni=>
H929	M1zuemdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Ml:xglUh\|ryP	MkXESG1UVw>?	NVjoUHlFUUN3ME2wMlAyPCEQvF2=	MWmxPVk6PjJ5Mh?=
PL45	NETNWHpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVj+OUDPxE1?	NIHWNlVFVVOR	M4DNTGlEPTB;Mj6yOVUh\|ryP	MnfpNVk6QTZ{N{K=
NCI-H383	NWm4XGl{T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MlfaglUh\|ryP	NGHuXXhFVVOR	NIPFOJZKSzVyPkWuNFAh\|ryP	MXyxPVk6PjJ5Mh?=
JJN3	MkT2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1i3T542KM7:TR?=	M13mZmROW09?	M{Hh[mlEPTB;Mj60N\|Mh\|ryP	MX6xPVk6PjJ5Mh?=
SU.86.86	MnT0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M4Xqbp42KM7:TR?=	NHHDWWdFVVOR	MX7JR\|UxRTJwNkeyJO69VQ>?	MnX4NVk6QTZ{N{K=
H1299	NFjPTINIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MYX+OUDPxE1?	M4rnRmROW09?	MWPJR\|UxRjVwMECg{txO	NETROVMyQTl7NkK3Ni=>
MDA-MB-468	MmTZS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Moq1glUh\|ryP	MoewSG1UVw>?	NF3RTFFKSzVyPUCuOVA1KM7:TR?=	MoGzNVk6QTZ{N{K=
SW1990	MojCS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFPSdnF,PSEQvF2=	NFTOXYJFVVOR	NYDEcphDUUN3ME2wMlgzPiEQvF2=	M1jWb\|E6QTl4Mkey
Calu-6	MYPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mo\KglUh\|ryP	M17MVGROW09?	M3yzbGlEPTB-NT6wNEDPxE1?	MVmxPVk6PjJ5Mh?=
MDA-MB-231	NFjTTnFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MkK5glUh\|ryP	NEHl[FlFVVOR	Mn25TWM2OD1zLk[0PEDPxE1?	M1jMSVE6QTl4Mkey
SW-684	NXy2[pQxT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NEHkenl,PSEQvF2=	Mk\vSG1UVw>?	NYm3UZhpUUN3ME61MlAxKM7:TR?=	MYmxPVk6PjJ5Mh?=
H209	MUTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M2PMcJ42KM7:TR?=	NHfQS5NFVVOR	MWrJR\|UxRTFwMUmzJO69VQ>?	MU[xPVk6PjJ5Mh?=
MDA-MB-231T	NEnET5NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3;rNp42KM7:TR?=	NVOxeJB3TE2VTx?=	MV\JR\|UxRjVwMECg{txO	M4rteVE6QTl4Mkey
HT1080/S	M1vCVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NUDtcmM5hjVizszN	MoPlSG1UVw>?	Mm\QTWM2OD1yLkWzNUDPxE1?	Mo\zNVk6QTZ{N{K=
H526 0.044	M2PRbGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NU\QOGh{hjVizszN	Mof4SG1UVw>?	MoXhTWM2OD1yLkC0OEDPxE1?	M3fEVFE6QTl4Mkey
DU4475 2.431	MmfkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWj+OUDPxE1?	NUnCOGlNTE2VTx?=	Ml7MTWM2OD1{LkSzNUDPxE1?	MV2xPVk6PjJ5Mh?=
HCT116	NEDxW2ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MoOyglUh\|ryP	MmC2SG1UVw>?	MljYTWM2OD1yLki1NkDPxE1?	NGfLZYIyQTl7NkK3Ni=>
M109	MoPzS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M2W5eJ42KM7:TR?=	MlrvSG1UVw>?	M4\0UmlEPTB;MT6wOVUh\|ryP	MmDTNVk6QTZ{N{K=
BT549	MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MWf+OUDPxE1?	NIezToxFVVOR	NIrjWXhKSzVyPUGuOlQ2KM7:TR?=	NYS1WIZLOTl7OU[yO\|I>
HCT116/VM46	NIfmdHpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2jiTp42KM7:TR?=	NVnofJZkTE2VTx?=	MYLJR\|UxRTFwN{CyJO69VQ>?	NFrTRVkyQTl7NkK3Ni=>
H460	MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MWP+OUDPxE1?	Ml;nSG1UVw>?	M1jHT2lEPTB;MD63PVUh\|ryP	M1nx[FE6QTl4Mkey
MCF-7	Mn\OS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MmTTglUh\|ryP	M2PTSGROW09?	NYj0Z4Y{UUN3ME2wMlAyPiEQvF2=	NU\sb282OTl7OU[yO\|I>
GEO	M3n6NWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NWnMcoxphjVizszN	M3yxUmROW09?	M3TCTWlEPTB;MD6zOVYh\|ryP	Ml;5NVk6QTZ{N{K=
H441 0.646	M3jvUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MV7+OUDPxE1?	NVmzSVltTE2VTx?=	NFf4fnlKSzVyPUCuOlQ3KM7:TR?=	MkLoNVk6QTZ{N{K=
MCF-7-807R	MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYW4ZYR7hjVizszN	NWDaSFlPTE2VTx?=	M1W5dWlEPTB;MD60PUDPxE1?	MYCxPVk6PjJ5Mh?=
Colo205	NIi3SY1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MUj+OUDPxE1?	MVzEUXNQ	M4X3PGlEPTB;MD6xNFQh\|ryP	MYOxPVk6PjJ5Mh?=
H292	NFq2VZVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MkfGglUh\|ryP	MVrEUXNQ	MWrJR\|UxRTBwN{i4JO69VQ>?	MWSxPVk6PjJ5Mh?=
BT474 (S)	NH2wRm1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NVLQWHVphjVizszN	M4nWS2ROW09?	MXXJR\|UxRTJwNECzJO69VQ>?	NYfPSJM5OTl7OU[yO\|I>
HT-29	MkmyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NF;IUHJ,PSEQvF2=	NVjzdHdHTE2VTx?=	NFXJSnBKSzVyPUKuNVA{KM7:TR?=	Mnq2NVk6QTZ{N{K=
A549	M1zjTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Ml;BglUh\|ryP	NWXzcGx{TE2VTx?=	NVu3OYg2UUN3ME2wMlY4PSEQvF2=	MU[xPVk6PjJ5Mh?=
BT474-M1	MoPES5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MmTNglUh\|ryP	M1nTOGROW09?	Mmi5TWM2OD1{LkO2OUDPxE1?	MYOxPVk6PjJ5Mh?=
SW480	NVrn[XRjT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NUS1V2p1hjVizszN	M1jOTGROW09?	MofRTWM2OD53LkCwJO69VQ>?	NF62XXgyQTl7NkK3Ni=>
L2987	M3nq[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MXf+OUDPxE1?	NEXCV3VFVVOR	M{LD[WlEPTB;MD60OFIh\|ryP	NXLEbopJOTl7OU[yO\|I>
AU565	MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MoXlglUh\|ryP	NEL4U2RFVVOR	Mn\FTWM2OD12Lkm3JO69VQ>?	M4TTbFE6QTl4Mkey
SW403	NF:zWVZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3jGcp42KM7:TR?=	MXHEUXNQ	NXO5O3dnUUN3ME2wMlIzKM7:TR?=	M1nle\|E6QTl4Mkey
H1437	NULDe2RCT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MWD+OUDPxE1?	M{TNcmROW09?	NES1ZpRKSzVyPUCuOVI{KM7:TR?=	NFrBbZAyQTl7NkK3Ni=>
BT-20	MorwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MVr+OUDPxE1?	MYPEUXNQ	M{jscGlEPTB;Mz61OlIh\|ryP	MoDUNVk6QTZ{N{K=
Colo320HSR	Mn35S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MknUglUh\|ryP	MkPJSG1UVw>?	NY[4UmpnUUN3ME2wMlAyOSEQvF2=	MlzFNVk6QTZ{N{K=
H2087	NF35TGZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NEC0b\|V,PSEQvF2=	NWnRVGlqTE2VTx?=	NHfod5lKSzVyPkGuNFAh\|ryP	MoLONVk6QTZ{N{K=
HCC1419	M1G1cWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NXvmfIE{hjVizszN	MoC4SG1UVw>?	MUHJR\|UxRTJwNUG3JO69VQ>?	Mk[3NVk6QTZ{N{K=
WiDr	MlnpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWf+OUDPxE1?	Mlq3SG1UVw>?	MnfvTWM2OD1yLkC3OkDPxE1?	MYOxPVk6PjJ5Mh?=
H661 0.573	MkjBS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXv+OUDPxE1?	NVLSWFFuTE2VTx?=	MYTJR\|UxRTBwNUezJO69VQ>?	NWrxdJlDOTl7OU[yO\|I>
HCC-38	NG\LPIFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NV3mS21PhjVizszN	M3fFXmROW09?	NUPq[noxUUN3ME61MlAxKM7:TR?=	MWKxPVk6PjJ5Mh?=
LS174T	Mo\mS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NHXwTZF,PSEQvF2=	MknhSG1UVw>?	NUnXbG1YUUN3ME2wMlU{PSEQvF2=	M37Ob\|E6QTl4Mkey
H211	MkTSS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWL+OUDPxE1?	MkHRSG1UVw>?	MX3JR\|UxRTBwN{OzJO69VQ>?	MkXyNVk6QTZ{N{K=
HCC70	M2P3RWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1X5PZ42KM7:TR?=	Ml\FSG1UVw>?	MmHTTWM2OD1zLkW1JO69VQ>?	NYGweXd4OTl7OU[yO\|I>
SW116	MorWS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFX3enN,PSEQvF2=	MUfEUXNQ	Mn;XTWM2OD1yLkC2O{DPxE1?	NIfXcGcyQTl7NkK3Ni=>
H513	NWfQXmVnT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NF7EcWp,PSEQvF2=	NV\nPY1DTE2VTx?=	M4L6SWlEPTB;ND60OFgh\|ryP	NH7JU5YyQTl7NkK3Ni=>
MDA-MB-157	MnvOS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NVTDTXJ7hjVizszN	M370emROW09?	MoCwTWM2OD1yLkCzOkDPxE1?	NIfDd4kyQTl7NkK3Ni=>
H2052	Mo\kS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1;aZZ42KM7:TR?=	NInYWplFVVOR	M3L0[mlEPTB;MT6wOUDPxE1?	M1LXflE6QTl4Mkey
MDA-MB-415	NXLiWHJIT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnzIglUh\|ryP	NYm0fG5MTE2VTx?=	NXm1eXRqUUN3ME61MlAxKM7:TR?=	NFTEZ3QyQTl7NkK3Ni=>
DLD-1	MYLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4\Hfp42KM7:TR?=	NG\3WmNFVVOR	M4TUNGlEPTB;MD65NFkh\|ryP	MV:xPVk6PjJ5Mh?=
H2595	NGnIdpRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MljJglUh\|ryP	M3\4TGROW09?	NYfyb3pYUUN3ME20MlQ4PSEQvF2=	MkLiNVk6QTZ{N{K=
MDA-MB-435S	NH;SZ3NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MlqxglUh\|ryP	MnKxSG1UVw>?	MYTJR\|UxRTFwOE[5JO69VQ>?	MYexPVk6PjJ5Mh?=
HCT15	M1vTd2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MYL+OUDPxE1?	NYrrUnZtTE2VTx?=	MXXJR\|UxRjFwMECg{txO	NFnwWHoyQTl7NkK3Ni=>
SK-Hep1	NG\zV\|hIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Mm[wglUh\|ryP	MUXEUXNQ	NUXpZlFXUUN3ME2wMlE1PiEQvF2=	NYHaPWo3OTl7OU[yO\|I>
MDA-MB-436	NV;EcFkzT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MV\+OUDPxE1?	NVnvNYN6TE2VTx?=	NHX1PIxKSzVyPUWuOVAzKM7:TR?=	MmjSNVk6QTZ{N{K=
KM12C	MnzYS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1;SR542KM7:TR?=	MmPOSG1UVw>?	M1\lTWlEPTB;MD6wOVQh\|ryP	MWSxPVk6PjJ5Mh?=
HEPG2	M4DaTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M{LSeJ42KM7:TR?=	Mn7QSG1UVw>?	NHrKOWFKSzVyPUCuNFI2KM7:TR?=	MWixPVk6PjJ5Mh?=
MDA-MB-453	NGfmdmxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2[x[J42KM7:TR?=	M2fUVGROW09?	M4X2c2lEPTB;MT64Olkh\|ryP	NFPaSYYyQTl7NkK3Ni=>
KM12SM	M3rCWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MXH+OUDPxE1?	NHjX[XlFVVOR	NGDi[IZKSzVyPUCuNFU6KM7:TR?=	NGLVOFcyQTl7NkK3Ni=>
1483	Ml;5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Mmf5glUh\|ryP	M3PPSmROW09?	MXfJR\|UxRTJwMUmg{txO	MYexPVk6PjJ5Mh?=
Hs578t	NYm1c5Y3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MmDTglUh\|ryP	NYTLWpNnTE2VTx?=	M3nPXWlEPTB;MT6yPFch\|ryP	MVmxPVk6PjJ5Mh?=
LS180	MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MUj+OUDPxE1?	MoL0SG1UVw>?	NIn3[phKSzVyPUCuOlk3KM7:TR?=	M4HKZ\|E6QTl4Mkey
FaDu	M{Puemdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFvlO3d,PSEQvF2=	NXz6UIFYTE2VTx?=	NELWfJVKSzVyPUGuNlch\|ryP	MkTTNVk6QTZ{N{K=
ZR-75-1	Mn7aS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MVv+OUDPxE1?	MV;EUXNQ	MnrSTWM2OD1{LkC4OEDPxE1?	M2TGZ\|E6QTl4Mkey
LS513	NW\Vc3JvT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3n5VJ42KM7:TR?=	NVPHNFBqTE2VTx?=	NXrWfWZnUUN3ME2wMlE{PSEQvF2=	NIPBc4UyQTl7NkK3Ni=>
Detroit.562	NYrUSYhOT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1\Be542KM7:TR?=	MYHEUXNQ	MlnGTWM2OD1zLkG0JO69VQ>?	MYexPVk6PjJ5Mh?=
ZR-75-30	Mk[5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M{L5[Z42KM7:TR?=	MkXNSG1UVw>?	MUnJR\|UxRjVwMECg{txO	NYPtbZRSOTl7OU[yO\|I>
RKO-PM	NXXjXoI4T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NV[2T49{hjVizszN	NYX2[\|JzTE2VTx?=	NX64WJJ7UUN3ME2wMlI{OiEQvF2=	MmDENVk6QTZ{N{K=
Cal.27	Mk\HS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NEDWc2V,PSEQvF2=	M1XQO2ROW09?	Mkn5TWM2OD1{IN88US=>	MmrkNVk6QTZ{N{K=
KPL4	M3PJPWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NYHQWWRIhjVizszN	NYHzZ3FJTE2VTx?=	MnHITWM2OD1zLkK1NkDPxE1?	MUixPVk6PjJ5Mh?=
PKO-RM13	MX\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWT5cGdmhjVizszN	MkjWSG1UVw>?	MXzJR\|UxRTBwNEK1JO69VQ>?	MXuxPVk6PjJ5Mh?=
HS.53.T	MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFntZWF,PSEQvF2=	NVzM[pMyTE2VTx?=	NYnYOGoxUUN3ME2wMlc6KM7:TR?=	M1P0eFE6QTl4Mkey
EMT6	NWK2W2VWT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NYDQXZVmhjVizszN	NVntVJAyTE2VTx?=	MW\JR\|UxRTBwOEC2JO69VQ>?	NXXHO414OTl7OU[yO\|I>
SNU-C1	NHvLO\|NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M4HIWp42KM7:TR?=	M3ywZWROW09?	M1LLOWlEPTB;MD6wNFch\|ryP	MlL6NVk6QTZ{N{K=
SQCCY1	NV\BflJRT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MmnzglUh\|ryP	MoXvSG1UVw>?	MX;JR\|UxRTBwN{mg{txO	MVyxPVk6PjJ5Mh?=
SW480	M4foS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFn2SJV,PSEQvF2=	M1rQfWROW09?	MnX6TWM2OD1yLkCzO{DPxE1?	NXnZNmN4OTl7OU[yO\|I>
SCC9	NUX1PGNUT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MX3+OUDPxE1?	MkPLSG1UVw>?	MoPaTWM2OD1yLke1JO69VQ>?	NXmzNlExOTl7OU[yO\|I>
SK-LMS-1	NFfQRXhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NX3NRoFGhjVizszN	M17xR2ROW09?	Mn\TTWM2OD1yLk[4O{DPxE1?	MWqxPVk6PjJ5Mh?=
SCC25	MlXrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MUX+OUDPxE1?	NYn1b242TE2VTx?=	NV7COoE6UUN3ME2wMlY5KM7:TR?=	MY[xPVk6PjJ5Mh?=
U87	NEXvfFBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2XH[p42KM7:TR?=	NU\wTm1jTE2VTx?=	MYnJR\|UxRTBwOUWg{txO	NIfX[JYyQTl7NkK3Ni=>
SCC15	NUPGVow1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NXPEV3MyhjVizszN	NWSyfGdUTE2VTx?=	M{TVV2lEPTB;MD62O{DPxE1?	M1nBelE6QTl4Mkey
T98G	M3\tTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NIjjZlh,PSEQvF2=	NV:5WGxGTE2VTx?=	MlHWTWM2OD1zLkKxPEDPxE1?	NFrNVpMyQTl7NkK3Ni=>
SCC4	MX\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NEjhT2l,PSEQvF2=	NU\wd3ZYTE2VTx?=	M37CVGlEPTB;MD62N{DPxE1?	NW\XTWQ1OTl7OU[yO\|I>
U118	NHHvclFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmT1glUh\|ryP	NInyenNFVVOR	NXnYZnhjUUN3ME2xMlYyQCEQvF2=	NVK1WG51OTl7OU[yO\|I>
TU167	NHLEdINIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NWmxTGNwhjVizszN	M3yycmROW09?	M171O2lEPTB;ND61NkDPxE1?	NHnTcJQyQTl7NkK3Ni=>
NCI-H727	NHTRZWJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MlzMglEx6oDMzszN	NGPMbIlFVVOR	NV7V[nZ3UUN3ME20Nlghdk1?	M2nqbFIxOzh3N{S3
NCI-H720	M4e3UGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MkC0glEx6oDMzszN	MonOSG1UVw>?	MYHJR\|UxRTJwODFOwG0>	NF;JPJozODN6NUe0Oy=>
NCI-H835	NV62U4ljT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NVj6XJhohjFy4pEK{txO	MWDEUXNQ	M{DoZmlEPTB;MTFOwG0>	NHy2NY4zODN6NUe0Oy=>
NCI-H727	M2HDXGtqdmG\|ZTDhd5NigQ>?	MnfHglEx6oDMzszN	M4fhOmROW09?	MnrIbY5pcWKrdIOgZ49ve3SrdIX0bZZmKEmJRkHSJIF2fG:yaH;zdIhwenmuYYTpc44>	Ml;DNlA{QDV5NEe=
RD	NHjpV4pIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NH32RZp,OTEkgJtOwG0>		NFrmcIFKSzVyPUGuNVIhyrWP	MnLONlEzQTh5NEW=
Rh41	M1\Mcmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MorKglEx6oDMzszN		M2f3cWlEPTB;MD6wO{DDvU1?	NFOzbVMzOTJ7OEe0OS=>
Rh18	MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MV;+NVDjiIsQvF2=		M{fq[mlEPTB;ND65OkDDvU1?	NYD1fW5IOjF{OUi3OFU>
Rh30	MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MYH+NVDjiIsQvF2=		M{TXcmlEPTB;MD6xPUDDvU1?	NF\BdVczOTJ7OEe0OS=>
BT-12	NE\XbWZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M364[J4yOOLCit88US=>		NHjUVZVKSzVyPUCuO\|ghyrWP	NFHsU3ozOTJ7OEe0OS=>
CHLA-266	M4PoWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MYf+NVDjiIsQvF2=		Mn7JTWM2OD1yLki5JOK2VQ>?	MkXzNlEzQTh5NEW=
TC-71	MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MoW0glEx6oDMzszN		NX\0OVRqUUN3ME2wMlEyKML3TR?=	MoO3NlEzQTh5NEW=
CHLA-9	M{jJVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M2P1TZ4yOOLCit88US=>		MofqTWM2OD1yLkGyJOK2VQ>?	MXiyNVI6QDd2NR?=
CHLA-10	M1fuW2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MYD+NVDjiIsQvF2=		Mk\5TWM2OD1yLk[yJOK2VQ>?	NYHjbpJuOjF{OUi3OFU>
CHLA-258	MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NI\WeXZ,OTEkgJtOwG0>		MnfDTWM2OD1yLkK3JOK2VQ>?	NFX5dFYzOTJ7OEe0OS=>
GBM2	M4HWfGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MV;+NVDjiIsQvF2=		M3XJfmlEPTB;MT60O{DDvU1?	MYqyNVI6QDd2NR?=
NB-1643	NFfCbXdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M4TDeJ4yOOLCit88US=>		MUnJR\|UxRTBwMUKgxtVO	M4LEUlIyOjl6N{S1
NB-EBc1	NUPNVnc1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVz+NVDjiIsQvF2=		M3[5VGlEPTB;MD6zOUDDvU1?	NVXRTZRGOjF{OUi3OFU>
CHLA-90	M{PVUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFfhTG9,OTEkgJtOwG0>		M2fkN2lEPTB;MD63O{DDvU1?	NVvLeVg{OjF{OUi3OFU>
CHLA-136	NXrPUIVNT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NUO2eWdVhjFy4pEK{txO		MV7JR\|UxRTBwNUKgxtVO	NX:2OXF[OjF{OUi3OFU>
NALM-6	MonsS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MnTJglEx6oDMzszN		MYjJR\|UxRTBwNEmgxtVO	NEDuUJEzOTJ7OEe0OS=>
COG-LL-317	NFi0S\|NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NVfQUmQxhjFy4pEK{txO		M320N2lEPTB;MT6zPEDDvU1?	MUiyNVI6QDd2NR?=
RS4;11	NGrIfVNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NFrPRmt,OTEkgJtOwG0>		NXXIXVlIUUN3ME2wMlM5KML3TR?=	MkHNNlEzQTh5NEW=
MOLT-4	MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NUi2dI5FhjFy4pEK{txO		NXq1TXRzUUN3ME2wMlU{KML3TR?=	MmT1NlEzQTh5NEW=
CCRF-CEM	MVXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M{X3dZ4yOOLCit88US=>		MXvJR\|UxRTFwMUOgxtVO	NFnVdVMzOTJ7OEe0OS=>
Kasumi-1	NETmc\|RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2PjdJ4yOOLCit88US=>		MkLSTWM2OD1zLkKgxtVO	MmPRNlEzQTh5NEW=
Karpas-299	M{\GcWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MYD+NVDjiIsQvF2=		M{i2SWlEPTB;MT62OEDDvU1?	M3nobFIyOjl6N{S1
Ramos-RA1	MmHWS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MY\+NVDjiIsQvF2=		M4TteGlEPTB;MT6zNUDDvU1?	NUD4fXhLOjF{OUi3OFU>
Rh30	M4TWU2Z2dmO2aX;uJIF{e2G7			M4mzeYlv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?=	MmrsNlU6OjV\|N{i=
Rh41	MXLGeY5kfGmxbjDhd5NigQ>?			MojXbY5lfWOnczDhckBqdmO{ZXHz[UBw\iCVRlugdIhwe3Cqb4L5cIF1cW:w	NIHBT4YzPTl{NUO3PC=>
RD	M2\1UWZ2dmO2aX;uJIF{e2G7			NH7mfW9qdmS3Y3XzJIFvKGmwY4LlZZNmKG:oIGPGT{BxcG:\|cHjvdplt[XSrb36=	M3HLVVI2QTJ3M{e4
A549	M{O3OWtqdmG\|ZTDhd5NigQ>?	M2m1XVAvPeLCit88US=>	NHrYXGJFVVOR	M1mxb4lvcGmkaYTzJGlITi2LUj;JVkBi[3SrdnH0bY9v	NYfOUVZxOjZ7Mki1O\|g>
NCI-H358	MmS4T4lv[XOnIHHzd4F6	MVewMlXjiIsQvF2=	NUXmeXZ[TE2VTx?=	NYWyXmpCcW6qaXLpeJMhUUeILVnSM2lTKGGldHn2ZZRqd25?	NYXZdpN[OjZ7Mki1O\|g>
A549	MlrXSpVv[3Srb36gZZN{[Xl?	NYPZcHpuOC534pEK{txO	NFT6fYVFVVOR	M2XLWINifXOnczDhJINwdmO3coLlcpQh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSUuWIHHu[EBGWkt?	NWDWOFQzOjZ7Mki1O\|g>
NCI-H358	MWXGeY5kfGmxbjDhd5NigQ>?	NGrQNoExNjYkgJtOwG0>	NVP0OYl5TE2VTx?=	M3fhVINifXOnczDhJINwdmO3coLlcpQh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSUuWIHHu[EBGWkt?	NIHvPHAzPjl{OEW3PC=>
A549	Mlz3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3zQNp4yOOLCit88US=>	MVzEUXNQ	NWHqfGJXUUN3ME2wMlc3KM7:TR?=	M2W0RVI3QTJ6NUe4
NCI-H358	NWHUfY9xT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXT+NVDjiIsQvF2=	M1rjcGROW09?	NYPkdYR3UUN3ME2xMlA6KM7:TR?=	MX6yOlkzQDV5OB?=
A549	NGS2NGtCeG:ydH;zbZMh[XO\|YYm=	NXraRpZvOC534pEK{txO	M1zLdGROW09?	M1TzeIlv\HWlZYOgRZBweHSxc3nz	MmTCNlY6Ojh3N{i=
NCI-H358	MnrsRZBweHSxc3nzJIF{e2G7	NIe2NWIxNjYkgJtOwG0>	M3SzT2ROW09?	M1r2T4lv\HWlZYOgRZBweHSxc3nz	NF3TWVMzPjl{OEW3PC=>
A549	NY\sblc5TnWwY4Tpc44h[XO\|YYm=	MkPzNE426oDMzszN	M4fZVmROW09?	NXO5d5lnemWmdXPld{B4d3WwZDDjcI9{fXKn	MoXhNlY6Ojh3N{i=
NCI-H358	NIXkfWNHfW6ldHnvckBie3OjeR?=	NFzM[VMxNjYkgJtOwG0>	MWjEUXNQ	NFPtZmVz\WS3Y3XzJJdwfW6mIHPsc5N2emV?	MoL1NlY6Ojh3N{i=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-IGFIRRβ/InsRβ / IGFIRβ / p-AKT / AKT / p-ERK / ERK ; PubMed: 26136493 Neuro Oncol (C) T4105 cells were treated with OSI-906 or BMS-754807 at indicated concentrations for 24 hours, lysed, and subjected to immunoblotting.	26136493
Growth inhibition assay	Cell viability; PubMed: 30754629 Molecules Response of SK-CO-1 to various drugs and drug combinations.	30754629

体内研究

BMS-754807(12.5mg/kg,口服)作用于携带 IGF-1R-Sal肿瘤的裸鼠，抑制肿瘤和血清中IGF-1R磷酸化。BMS-754807作用于一组选定的上皮(IGF-1R-Sal, GEO, 和Colo205），造血（JJN3）和间质（RD1和Rh41）移植瘤模型，抑制肿瘤生长，肿瘤生长抑制率从53％至115％不等。^[1] BMS-754807 (6.25 mg/kg) 作用于转基因的IGF-Sal肿瘤小鼠模型，完全抑制肿瘤生长，且抑制pIGF-1R 和 pAKT。BMS-754807与小鼠血浆和人类血浆的蛋白结合率分别为98.5% 和95.9%。BMS-754807 (25 mg/kg)作用于携带KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), 和 OS-1移植瘤的小鼠模型，显著抑制肿瘤。^[3]

激酶实验：^[1]	- 合并激酶抑制实验: 在体外激酶实验中使用重组人类 IGF-1受体酶测定BMS-754807，在生化实验中使用合成肽KKSRGDYMTMQIG 作为磷酸受体底物测定BMS-754807。在Ubottom 384孔板中使用 30 μL实验缓冲液 (100 mM Hepes pH 7.4, 10 mM MgCl₂, 0.015% Brij35 and 4 mM DTT)来进行酶活测定。通过结合ATP，1.5 μM 荧光标记肽底物, 酶和BMS-754807而开始反应，反应持续60分钟。加入EDTA终止反应。通过电泳分离荧光底物和磷酸化产物，然后在Caliper LabChip 3000上分析反应混合物。通过对剂量反应曲线进行非线性回归分析而获得IC50值。
细胞实验：^[1]	- 合并 Cell lines: IGF-1R-Sal, RH41 和 Geo 细胞系 Concentrations: 365 nM Incubation Time: 72 小时 Method: 细胞按最佳密度培养在RPMI + GLUTAMAX培养基中，培养基中含有有10％热灭活的胎牛血清（FBS），10mMHepes，青霉素和链霉素。BMS-754807处理细胞72小时后，通过测定³H-胸甘渗透到DNA中的程度而测评细胞增殖。结果表示为IC50。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 携带IGF-1R-Sal, GEO, Colo205, JJN3, RD1 或 Rh41 肿瘤的裸鼠 Dosages: 150 mg/kg Administration: 口服 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	92 mg/mL (199.35 mM)
	Ethanol	92 mg/mL (199.35 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+30% PEG 300+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download BMS-754807 SDF

分子量	461.49
化学式	C₂₃H₂₄FN₉O
CAS号	1001350-96-4
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

选择性强的IGF-1R抑制剂

NVP-AEW541 : IGF-1R-selective, IC50=86 nM.
用于临床的IGF-1R抑制剂

OSI-906 (Linsitinib) : Phase II for Advanced Solid Tumors.
最新的IGF-1R抑制剂

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.
经典的IGF-1R抑制剂

BMS-536924 : ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

研究领域

产品类型

定制您的化合物库

BMS-754807

客户使用Selleck生产的BMS-754807发表文献29篇：

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download BMS-754807 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

相关IGF-1R产品